abrdn Life Sciences Investors (NYSE:HQL) Stock Price Down 0.1% – Should You Sell?

by · The Markets Daily

Shares of abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) fell 0.1% during trading on Wednesday. The company traded as low as $17.32 and last traded at $17.5450. Approximately 92,927 shares traded hands during mid-day trading, a decline of 30% from the average daily volume of 133,602 shares. The stock had previously closed at $17.56.

abrdn Life Sciences Investors Trading Up 4.2%

The firm has a fifty day moving average of $20.07 and a 200-day moving average of $18.78.

abrdn Life Sciences Investors Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Monday, August 24th were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Monday, August 24th. This represents a $2.48 annualized dividend and a dividend yield of 13.7%.

Hedge Funds Weigh In On abrdn Life Sciences Investors

Hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC grew its position in abrdn Life Sciences Investors by 57.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 362,535 shares of the company’s stock worth $5,898,000 after buying an additional 132,098 shares in the last quarter. 180 Wealth Advisors LLC boosted its holdings in shares of abrdn Life Sciences Investors by 2.2% in the 2nd quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after purchasing an additional 3,271 shares in the last quarter. Formidable Asset Management LLC increased its stake in shares of abrdn Life Sciences Investors by 27.3% in the 1st quarter. Formidable Asset Management LLC now owns 158,385 shares of the company’s stock valued at $2,658,000 after purchasing an additional 33,940 shares during the last quarter. Royal Bank of Canada lifted its position in shares of abrdn Life Sciences Investors by 16.5% during the 1st quarter. Royal Bank of Canada now owns 121,240 shares of the company’s stock worth $1,972,000 after buying an additional 17,152 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in abrdn Life Sciences Investors by 8.6% during the first quarter. Bank of America Corp DE now owns 115,585 shares of the company’s stock worth $1,881,000 after acquiring an additional 9,145 shares in the last quarter. 32.21% of the stock is owned by institutional investors.

abrdn Life Sciences Investors Company Profile

(Get Free Report)

abrdn Life Sciences Investors (NYSE: HQL) is a diversified, closed-end investment company focused on the life sciences sector. The fund seeks long-term capital appreciation by investing in companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services and related industries.

Its portfolio may include both publicly traded and privately held businesses across various stages of development, from emerging companies developing new therapies and technologies to more established healthcare enterprises.

Recommended Stories